Drug Type Small molecule drug |
Synonyms Cefotetan disodium (USP), Cefotetan sodium (JAN), ICI-156834 (free acid) + [5] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Dec 1985), |
Regulation- |
Molecular FormulaC17H17N7NaO8S4 |
InChIKeyBTOFDTWBLNLGSY-DWUNWFSHSA-N |
CAS Registry74356-00-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02228 | Cefotetan Disodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bone and joint infections | US | 09 Aug 2007 | |
Gynecological infection | US | 09 Aug 2007 | |
Intraabdominal Infections | US | 09 Aug 2007 | |
Lower Respiratory Tract Infections | US | 09 Aug 2007 | |
Skin and skin structure infections | US | 09 Aug 2007 | |
Urinary Tract Infections | US | 09 Aug 2007 | |
Infectious Diseases | US | 27 Dec 1985 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Complicated intra-abdominal infection | Phase 2 | CN | 21 Feb 2017 | |
Bacterial Infections | Phase 2 | CN | 10 Oct 2012 | |
Genitourinary tract infection | Phase 2 | CN | 12 Apr 2012 | |
Skin Diseases, Infectious | Phase 1 | CN | 09 Mar 2015 | |
Acute Bronchitis | Phase 1 | CN | 26 Jul 2011 | |
Bronchiectasis | Phase 1 | CN | 26 Jul 2011 | |
Bronchitis, Chronic | Phase 1 | CN | 26 Jul 2011 | |
Pneumonia | Phase 1 | CN | 26 Jul 2011 |